Exchange: NASDAQ·Updated 07:34 PM EDT
News
all
press releases
Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?
NVO heads into Q2 earnings under pressure as slowing injectable GLP-1 momentum, pricing headwinds and fierce competition cloud the near-term outlook.
Zacks
More News
VKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’t
Viking expects oral VK2735 Phase 3 studies to begin in Q4 and believes the pill could become the first oral dual GLP-1 agonist to reach the market.
Stocktwits
How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q2 Results?
Novo Nordisk's Q2 results are set to spotlight Ozempic and Wegovy sales as oral launches and label expansions drive growth amid mounting competitive pressure.
Zacks
LLY's Retatrutide Nears 2027 Filing With Two More Phase III Wins
Eli Lilly's retatrutide meets the primary endpoint in the phase III TRIUMPH-2 & TRIUMPH-3 studies, supporting planned regulatory submissions for obesity in 2027.
Zacks
How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q2 Results?
LLY's blockbuster GLP-1 portfolio takes center stage as investors watch Mounjaro, Zepbound and Foundayo for clues to Q2 growth and outlook.
Zacks
NVO Challenges LLY Ads in GLP-1 Battle: Why the Lawsuit Matters Now
Novo Nordisk sues LLY over high-profile ads promoting Zepbound and Mounjaro, arguing newer clinical data changes the comparison as the GLP-1 rivalry intensifies.
Zacks
Does EU Approval of Wegovy Pill Change NVO's Competitive Story?
Novo Nordisk wins EU approval for the first GLP-1 obesity tablet, expanding Wegovy's reach, but tougher competition keeps the broader investment outlook in focus.
Zacks
NVO Rallies 11% in a Month: How Should Investors Play the Stock?
Novo Nordisk stock gains 11% in a month as Wegovy access expands and U.K. approval boosts optimism, but rising competition and earnings pressure cloud the outlook.
Zacks
LLY Hits Another Record High: Is the Stock Too Expensive to Buy Now?
Eli Lilly hits another record high as confidence grows in its obesity and diabetes portfolio, with Wall Street still seeing upside despite the rich valuation.
Zacks
Structure Therapeutics (GPCR) Is A Hidden Biotech Multibagger Stock To Buy Now
Structure Therapeutics (GPCR) Is A Hidden Biotech Multibagger Stock To Buy Now...
Yahoo! Finance: News

Advertisement|Remove ads.